The U.S. Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) injection, marking the first treatment shown to help patients with a severe form of Niemann-Pick disease type C (NPC) live longer. The approval was announced on November 17, 2026.

Lembaz is indicated to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, a condition known as infantile-onset NPC. The therapy is administered as an intrathecal injection every two weeks by a trained healthcare provider.

To evaluate the drug's efficacy, the FDA reviewed data from three clinical studies and an expanded access program involving 36 patients. The analysis showed that patients treated with Lembaz had a 55% reduction in the risk of death compared to a matched external control group. The median survival time was 8.5 years for the treated group, compared to 4.9 years in the control group.

The FDA granted Breakthrough Therapy designation to Lembaz. The drug is manufactured by Mandos, LLC, a subsidiary of Beren Therapeutics, PBC. Common side effects include problems with hearing, balance, and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including potential permanent hearing loss, and requires comprehensive hearing evaluations before and during treatment.